Email Updates

You are here

Home

5 FEBRUARY 2021 VOLUME 23 ISSUE 5

Media Coverage

  • Exclusive: 5 potential picks to succeed Deborah Birx at PEPFAR

    President Joe Biden has yet to announce a nominee for US global AIDS coordinator, the role that was previously held by Deborah Birx and includes leadership of the US President’s Emergency Plan for AIDS Relief, or PEPFAR.

    February 4, 2021
    General
    Devex

  • Health Care Providers Aren't Talking to Black Women About PrEP

    Though HIV infection rates are decreasing across the US, Black women are still being pummeled by the virus. Yes, Black women saw a 21 percent decrease in seroconversions between 2010 and 2016, but they also accounted for 57 percent of new HIV infections among all women in 2018. Keep in mind that Black women make up less than 7 percent of the population in this country.

    February 4, 2021
    PrEP
    The Body

  • First-in-Human Clinical Trial Confirms New HIV Vaccine Approach

    After decades of searching for an HIV vaccine, a scientist has finally made a breakthrough with a new approach to developing a vaccine against the virus. The findings of the trial were presented at the International AIDS Society HIV Research for Prevention conference.

    February 4, 2021
    HIV Vaccine
    Health 24

  • Tenofovir Vaginal Rings May Best Dapivirine for Cyclic HIV Protection

    Separate trials of vaginal rings for HIV and pregnancy prevention found very different levels of antiretrovirals during periodic removal depending on the prevention drug used, according to data presented at the 4th HIV Research for Prevention virtual conference.

    February 3, 2021
    Microbicides
    POZ

  • Meet the New Gilead Exec in Charge of Work on an HIV Vaccine and More

    "I can see a better health future on the horizon. I strive for that every day," says Jared Baeten, vice president of virology clinical research at Gilead.

    February 3, 2021
    HIV Vaccine
    San Francisco Business Times

  • The Buenos Aires Patient: Argentinian Woman Controls HIV for at Least 12 Years After Stopping Treatment

    An Argentinian woman, now in her 50s, has controlled HIV below the limits of detection since stopping HIV treatment due to side-effects in 2007, researchers from Buenos Aires and the US National Institutes of Health report.

    February 3, 2021
    General
    aidsmap

  • ‘Vaccine Nationalism’ Echoes the Disastrous Mistakes Made With HIV

    Though HIV and Sars-CoV-2 are very different viruses, the Covid-19 pandemic has highlighted striking parallels: governments being too slow to respond; a marked impact on minority communities and a failure to understand why; a governmental response which has veered into overpolicing and victim-blaming, rather than taking every conceivable measure to help people stay safe and healthy. I watch with growing consternation as the world repeats the mistakes of the early response to HIV.

    February 2, 2021
    General
    The Guardian

  • African Nations Lead the World in Offering PrEP HIV Prevention Drug

    Nearly 1 million people are now taking pre-exposure prophylaxis (PrEP), medicine that can slash the risk of HIV infections. While early use of the drug was mostly limited to Western nations, the number of users in sub-Saharan Africa (SSA) has now drastically increased, accounting for more than half of the world’s PrEP users.

    February 2, 2021
    PrEP
    New Scientist

  • Medical Male Circumcision Gaining Popularity Among Zambian Men

    Male circumcision is not a new thing in Zambia. Communities mainly in the Northwestern Province of the country and a few other places have long practiced it usually as a rite of passage for boys. However, medical male circumcision, which is the removal of the foreskin of the male reproductive organ by a medical expert, is gaining popularity among men in Zambia.

    February 1, 2021
    Voluntary Medical Male Circumcision
    Xinhua

  • Nearly a Million Have Started Taking PrEP Worldwide – Only a Third of UNAIDS’ 2020 Target

    Despite the incredible efficacy of oral pre-exposure prophylaxis (PrEP) and 78 countries currently offering PrEP in some form, its effectiveness at reducing HIV incidence in the real world has been dependent on far-reaching factors that go beyond how well PrEP is able to prevent HIV acquisition at a cellular level: political leadership, quality health services and funding.

    February 1, 2021
    PrEP
    aidsmap

  • Gilead Sciences Pens Early-Stage HIV Vaccine Pact With Gritstone Oncology

    Initially known as a machine learning biotech focused on cancer, Gritstone Oncology has been broadening its scope to include a very early look at treatments for COVID-19 and, now, another infectious disease. In a $60 million upfront equity split payment, Big Pharma Gilead Sciences is pairing up with Gritstone for an HIV therapeutic vaccine the pair believes could be curative for the disease.

    February 1, 2021
    HIV Vaccine
    Fierce Biotech

  • Opinion: Biden’s PEPFAR Could Create the First AIDS-Free Generation

    Dr. Anthony Fauci signaled renewed urgency in a statement at last week’s World Health Organization executive board meeting resulting in a sigh of relief across the global health community. “The Biden Administration … intends to be fully engaged in advancing global health, supporting global health security and the Global Health Security Agenda, and building a healthier future for all people.”

    January 28, 2021
    General
    Devex

  • IPM Pursuing Regulatory Approvals for the Dapivirine Ring’s Use in Eastern and Southern Africa

    Non- profit International Partnership for Microbicides (IPM) says it is pursuing regulatory approvals for the dapivirine ring’s use in eastern and southern Africa (ESAR) Region, where the need is particularly urgent. This follows Tuesday’s recommendation by the World Health Organization (WHO) that the monthly dapivirine ring may be offered as an additional prevention choice for women at substantial risk of HIV infection.

    January 28, 2021
    Microbicides
    The Herald Zimbabwe

  • Important Advances in HIV Prevention Unveiled: New PrEP Formulas & Broadly Neutralizing Antibodies

    While global attention has fixated on the coronavirus, the forty-year long fight against HIV, which has claimed 33 million lives, is seeing new breakthroughs in preventive tools. New discoveries of “broadly neutralizing antibodies” as well as novel regimens of pre-exposure prophylaxis (PrEP), could strengthen the world’s toolbox to prevent the disease, announced the International AIDS Society (IAS) at the opening of the 4th HIV Research for Prevention Conference.

    January 27, 2021
    Antibody Related Research, PrEP
    Health Policy Watch

Published Research

Announcements